Cue Biopharma
CUE
49 hedge funds and large institutions have $10.4M invested in Cue Biopharma in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 12 closing their positions.
233% more call options, than puts
Call options by funds: $20K | Put options by funds: $6K
0.02% less ownership
Funds ownership: 0.62% → 0.6% (-0.02%)
9% less funds holding
Funds holding: 54 → 49 (-5)
19% less capital invested
Capital invested by funds: $12.8M → $10.4M (-$2.44M)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$321K |
| 2 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
+$112K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$77.5K |
| 4 |
Renaissance Technologies
New York
|
+$45.8K |
| 5 |
Squarepoint
New York
|
+$18.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GLA
Good Life Advisors
Reading,
Pennsylvania
|
-$436K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$150K |
| 3 |
Millennium Management
New York
|
-$75.5K |
| 4 |
Jane Street
New York
|
-$69.5K |
| 5 |
HF
HRT Financial
New York
|
-$53K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Millennium Management
New York
| – | -$75.5K | -2,310 | Closed |
|
|
52
Jane Street
New York
| – | -$69.5K | -2,126 | Closed |
|
|
HF
53
HRT Financial
New York
| – | -$53K | -1,635 | Closed |
|
|
PAS
54
Point72 Asia (Singapore)
Singapore
| – | -$30.3K | -925 | Closed |
|
|
VF
55
Virtu Financial
New York
| – | -$18K | -561 | Closed |
|
56
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$14.5K | -442 | Closed |
|
|
CSS
57
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$3.99K | -122 | Closed |
|
|
LFG
58
Larson Financial Group
St Louis,
Missouri
| – | -$1.53K | -47 | Closed |
|
59
Fidelity Investments
Boston,
Massachusetts
| – | -$105 | -3 | Closed |
|
|
PD
60
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$72 | -2 | Closed |
|
61
Citigroup
New York
| – | -$47 | -1 | Closed |
|
|
SS
62
SBI Securities
Tokyo,
Japan
| – | -$1 | – | – |
|
CUE Hedge Fund Activity: Q1 2025 in Review
49 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2025, worth a combined $10.4M — down 19% from $12.8M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CUE and 7 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $321K. The largest seller was Good Life Advisors, exiting entirely with an estimated $436K sold.
- 49 institutional investors held Cue Biopharma (CUE) as of Q1 2025, down from 54 in Q4 2024.
- Funds reported $10.4M of Cue Biopharma stock for Q1 2025, down 19% quarter-over-quarter.
- 7 funds opened new Cue Biopharma positions in Q1 2025 and 12 closed out, a net change of -5 holders.
- The largest Cue Biopharma buyer in Q1 2025 was Vanguard Group, an estimated $321K added.
- The largest Cue Biopharma seller in Q1 2025 was Good Life Advisors, an estimated $436K sold.
Based on aggregated 13F filings for Q1 2025.